Intracranial antitumor efficacy of combination treatment with encorafenib plus binimetinib in BRAF V600E-mutated anaplastic thyroid carcinoma
{{output}}
The intracranial antitumor efficacy of combination therapy with BRAF and MEK inhibitors in BRAF-mutated thyroid cancer has not been reported. Here, we describe a case of anaplastic thyroid cancer harboring BRAF V600E mutation with brain metastases which was tr... ...
